4.6 Review

Endocrine toxicities of immune checkpoint inhibitors

期刊

NATURE REVIEWS ENDOCRINOLOGY
卷 17, 期 7, 页码 389-399

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41574-021-00484-3

关键词

-

资金

  1. NIH/NCI [K23 CA204726]
  2. NIH [R01CA227481, DK20593]
  3. NIDDK [T32DK007061]
  4. Doris Duke Charitable Foundation
  5. James C. Bradford Jr. Melanoma Fund
  6. Melanoma Research Foundation

向作者/读者索取更多资源

Immune checkpoint inhibitors (ICIs) have become a cornerstone of cancer therapeutics, but can also cause toxicities in various organs known as immune-related adverse events. ICIs can lead to endocrinopathies involving the thyroid, pituitary, adrenal glands, and pancreas, which are common and sometimes fatal.
Immune checkpoint inhibitors (ICIs) are now an established cornerstone of cancer therapeutics; however, ICIs are associated with toxicities in various organs, termed immune-related adverse events. This Review highlights current understanding in ICI-induced endocrinopathies, including epidemiology, aetiology, clinical manifestations and approaches to treatment. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab, are approved for the treatment of numerous and diverse cancer types, in various combination regimens, and are now an established cornerstone of cancer therapeutics. Toxicities induced by ICIs are autoimmune in nature and are referred to as immune-related adverse events (irAEs); these events can affect any organ system in an unpredictable fashion. Importantly, irAEs can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). These events are a frequent source of acute and persistent morbidity in patients treated with ICIs and can even be fatal. Over the past few years, there has been a growing understanding of the underlying pathogenesis of irAEs that has led to the development of more effective management strategies. Herein, we review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from ICIs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据